Dupuytren’s disease Musculoskeletal Diseases
Conditions
Interventions
Vapocoolant spray group:
Application of commercially available menthol-based vapocoolant spray (Mentholatum Ice Spray, Australia) for 5 seconds at a distance of 10 cm to the injection site, immediatel
allocation concealed.
Patients and the injecting surgeon are blinded until the moment of spray application.
Sponsors
Peninsula Health
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Adults aged =18 years undergoing PNA for Dupuytren’s disease 2. Disease affecting a single hand with one or more involved rays 3. Able to provide informed consent
Exclusion criteria
Exclusion criteria: 1. Known allergy or hypersensitivity to lignocaine 2. Prior sensory deficit or paraesthesia in the affected hand 3. Cognitive impairment affecting reliable pain assessment 4. Inability to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Injection pain measured using a 10-point Visual Analogue Scale (VAS) immediately after the first local anaesthetic infiltration | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Immediate adverse events (allergic reactions, vasovagal response, unusual sensations) recorded at the time of infiltration 2. Perioperative complications (infection, bleeding, neurovascular injury) recorded during and after PNA 3. Correlation between injection pain and patient demographic variables (age, sex, comorbidities) and disease severity (Tubiana grade) using Spearman’s correlation coefficients | — |
Countries
Australia
Contacts
Public ContactIshith Seth
Outcome results
None listed